Mutation and Abnormal Expression of the p53 Gene in the Viral Skin Carcinogenesis of Epidermodysplasia Verruciformis  by Padlewska, Kamila. et al.
Mutation and Abnormal Expression of the p53 Gene in the
Viral Skin Carcinogenesis of Epidermodysplasia Verruciformis
Kamila Padlewska,*² Nicolas Ramoz,* Patricia Cassonnet,* Guy Riou,³ Michel Barrois,³ Slavomir Majewski,²
Odile Croissant,* Stefania Jablonska,² and GeÂrard Orth*
*UniteÂ des Papillomavirus, Institut Pasteur, Paris, France; ²Department of Dermatology, Warsaw School of Medicine, Warsaw, Poland; ³Laboratoire de
Pharmacologie Clinique et MoleÂculaire, Institut Gustave Roussy, Villejuif, France
Patients suffering from epidermodysplasia verrucifor-
mis are prone to nonmelanoma skin cancers, due to
an inherited abnormal susceptibility to the oncogenic
human papillomavirus type 5. Genotoxic sunlight
ultraviolet B radiations are likely to be a cofactor.
Lesions of two human-papillomavirus-type-5-
infected epidermodysplasia verruciformis patients
collected during an 8 y period were retrospectively
studied for p53 mutations in exons 5 through 8 by a
polymerase chain reaction single-strand conform-
ation polymorphism technique and/or by DNA
sequencing of ampli®ed exons. Mutations were
detected in 11 of 26 (42.3%) specimens, including
®ve (62.5%) squamous cell carcinomas, three (33.3%)
Bowen's carcinomas in situ, two (40%) actinic kera-
toses, and one (33%) benign lesion. The nine muta-
tions characterized by sequencing were shown to be
missense and to affect mutational hotspots in human
cancers. Five were C®T transitions at dicytidine
sites considered as ultraviolet signature mutations.
Two were transversions (C®G and C®A) at dicyti-
dine sites and two were C®T transitions at nondi-
pyrimidine sites. A marked p53 immunoreactivity
was disclosed in 72.7% of 11 invasive carcinomas,
55.6% of nine carcinomas in situ, 37.5% of eight acti-
nic keratoses, and one of three benign lesions. This
includes 81.8% of 11 specimens with a p53 mutation
but also 50% of 14 specimens with no mutation
detected. A dysfunction of the p53 gene is thus likely
to play a part in epidermodysplasia verruciformis
carcinogenesis, either due to ultraviolet-B-induced
p53 mutations, as in nonmelanoma skin cancers in
the general population, or involving other mutagens
or mechanisms. The part played by human papillo-
mavirus type 5 proteins expressed in epidermodys-
plasia verruciformis keratinocytes remains to be
determined. Key words: genodermatosis/human papillo-
mavirus type 5/immunohistochemistry/nonmelanoma skin
cancer/PCR-SSCP. J Invest Dermatol 117:935±942, 2001
E
pidermodysplasia verruciformis (EV) is a rare genoder-
matosis associated with a high risk of nonmelanoma skin
cancer (NMSC) that provides a model for studying
interactions between potentially oncogenic human
papillomaviruses (HPV) and sunlight in skin carcino-
genesis (Orth, 1987; Majewski and Jablonska, 1995). EV results
from a genetically determined abnormal susceptibility to infection
with a speci®c group of related HPV genotypes (EV HPV), as well
as to the oncogenic potential of some of them, especially HPV5
(Ramoz et al, 2000; Orth et al, 2001). Infection leads to the
development of disseminated, persistent ¯at wart-like and macular
lesions, usually starting in early childhood. Upon their third or
fourth decade, about half of EV patients start developing multiple
precancerous lesions of the skin [actinic keratosis (AK), Bowen's
carcinoma in situ (CIS)], which evolve into NMSC [mostly
squamous cell carcinomas (SCC)]. EV carcinomas harbor high copy
numbers of episomal HPV genomes (usually HPV5 or occasionally
HPV8, 14, 17, 20, or 47) and abundant transcripts of the E6 and E7
open reading frames (Orth, 1987). Phenocopies of EV are
exceptionally observed in immunosuppressed patients. EV HPV
cause widespread inapparent infections in the general population
(Boxman et al, 1997; Antonsson et al, 2000) but their role in skin
carcinogenesis in non-EV patients remains to be demonstrated
(Kawashima et al, 1990; P®ster and ter Schegget, 1997).
The viral and cellular molecular mechanisms leading to the early
development of skin malignancies in EV patients are still poorly
understood. By analogy with the development of HPV16- and
HPV18-associated anogenital carcinomas, the viral E6 and E7
proteins are likely to play a major part in tumor progression, by
targeting cellular proteins that negatively regulate the cell cycle
(Howley, 1996). HPV5 and HPV8 E7 proteins have been shown to
associate with retinoblastoma (Rb) protein, though with reduced
binding af®nities compared to HPV16 and HPV18 E7 proteins
(Yamashita et al, 1993; Schmitt et al, 1994). E2F transcription
factors, the key regulators of cell DNA replication, may thus be
released from their inactive Rb-bound forms (Hiraiwa et al, 1996).
In contrast to HPV16 and HPV18, the E6 proteins of oncogenic
EV HPV do not possess the ability to interact with p53 protein and
ubiquitin-protein ligase E6-AP, which would promote p53
degradation, and to inhibit p53-mediated transactivation of cellular
genes (Steger and P®ster, 1992; Kiyono et al, 1994; Elbel et al,
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1997). Strikingly, expression of the HPV5 E6 protein has recently
been reported to inhibit ultraviolet (UV) radiation-induced G1
arrest and apoptosis, in spite of increased levels of transcriptionally
active p53 protein (Jackson and Storey, 2000).
Malignant transformation of EV lesions usually occurs on sun-
exposed areas of the skin, which suggests that UV radiation may act
as a cofactor in the carcinogenesis process, through its mutagenic
and immunosuppressive effects (Orth, 1987; Majewski and
Jablonska, 1995). Sunlight, mainly its highly genotoxic UVB
component, represents the major environmental factor associated
with NMSC in the general population (Brash, 1997). It is well
established that the p53 gene is a major target of UV-induced
mutations and that inactivation of this gene is a common event in
the process of skin carcinogenesis in the general population (Dumaz
et al, 1994; Nataraj et al, 1995; Ren et al, 1996; Brash, 1997). p53
mutations have been detected in more than half of the cases of AK,
Bowen's disease, and NMSC. About two-thirds of the mutations
are C®T or, less frequently, CC®TT transitions that result from
unrepaired cyclobutane pyrimidine dimers and pyrimidine (6±4)
pyrimidone photoproducts (Brash et al, 1991; MoleÁs et al, 1993;
Ziegler et al, 1993; 1994). In response to DNA-damaging agents,
p53 protein has been shown to activate G1 and G2 cell cycle
checkpoints, to participate in nucleotide excision repair, and to
evoke apoptotic processes (Levine, 1997; Amundson et al, 1998).
Dysfunction of the p53 protein, through impaired sequence-
speci®c transactivation or protein±protein interactions, results in
genomic instability and is thus likely to play a crucial role in skin
carcinogenesis, as it does in more than 50% of all human
malignancies (Greenblatt et al, 1994).
As there is no evidence for an EV-HPV-induced inactivation of
the p53 protein, our aim was to analyze the status of the p53 gene at
various stages of the EV carcinogenesis process. We took advantage
of a collection of DNA preparations and paraf®n-embedded tissue
specimens from EV lesions taken over an 8 y period from two
patients suffering from this very rare disease. We searched for
mutations in the p53 gene or its abnormal expression and for over-
expression of the Bcl-2 protein, which is able to block p53-
dependent apoptosis (White, 1996; Amundson et al, 1998). We
wanted to determine at which step of the tumor progression these
events could occur, and whether the p53 mutation pattern ®tted
that of UV-induced mutations in NMSC of the general population.
MATERIALS AND METHODS
Patients Two patients of Polish origin, a woman born in 1940 with
a familial form of EV (patient A) and a man born in 1935 (patient B),
were included in the study. Both patients had almost generalized typical
benign ¯at wart-like and pityriasis versicolor-like lesions and reddish
plaques, which started to appear at the age of 5 y. Patients constantly
developed multiple, locally destructive malignant changes on the
forehead and other sun-exposed areas of the skin, from the age of 29 y
(patient A) or 39 y (patient B) to their death at the age of 56 y and 60 y,
respectively. Since 1977, repeated biopsy specimens from both patients
were analyzed by Southern blot hybridization of HindII- or PstI-
restricted tumor DNA using DNA probes speci®c for various HPV
Table I. Summarized data on EV tumor specimens and p53 status
Patient,
specimen
Year of
sampling Site
Histologic
diagnosisa
HPV
typeb
p53
exon 5±8c
p53
stainingd
A, a 1986 forearm ak 5,8 M7 2 +
A, b leg ak 9 N 3 +
A, c back cis 5,9 M5 (8) 3 +
A, d back cis 9 N 2 +
A, e thorax ak 5,9,36 N (5) ±
A, f hand cis 5,9,X M7; M7 +
A, g hand cis 5,8,9 M6 (5) +
A, h forehead cis 9,X N ±
A, i 1988 abdomen bl 9,36 M5 2 +
A, j ®nger ak 36 nc (6, 8) +
A, k forearm mscc 5 M8 (6) 2 +
A, l forearm mscc 5,X N +
A, m arm mscc 5,9 M7 3 +
A, n forearm SCC 5,8,9,36 N 3 +
A, o wrist ak 5,9,X nc (5±8) +
A, p ear BCC 5,8,36 N 2 +
A, q hand cis 5,9,X N +
A, r hand mscc 5,9,36 nc (5, 6, 8) +
A, s 1991 thorax ak 9,X nc (5, 6) ±
A, t thorax bl 9,X N (6) ±
A, u 1994 hand ak 9 N +
A, v neck cis 5,9 N 3 +
B, a 1986 forehead ak nc nc (7, 8); M7 3 +
B, b forehead mscc 5 M5 3 +
B, c 1987 back mscc 5 nc (6, 8) nc
B, d 1988 neck SCC 5 nc (5, 8) 3 +
B, e neck SCC 5 nc (5±8); M5 3 +
B, f 1989 forehead SCC 5 nc (5,6,8); M7 2 +
B, g 1990 back cis 5 nc (5,7); N 3 +
B, h 1993 forehead SCC 5 N ±
B, i 1994 back cis 5 N (8); N 3 +
B, j back bl 5,49 N (5) nc
aAs de®ned by the most severe histologic change: mscc, microinvasive SCC; cis, Bowen's CIS; ak, AK; bl, benign lesion.
bAs determined by Southern blot hybridization experiments. X, unidenti®ed EV HPV related type; nc, not conclusive because of DNA degradation.
cAs analyzed by PCR-SSCP. Numbers indicate mutated exons or, in parentheses, nonconclusive exons. N, normal for at least three exons; M, mutation; nc, nonconclu-
sive. In italics, data obtained from microdissected tissue sections.
dp53 immunoreactivity was scored as (±) for less than 1%, (+) for 1%±30%, (2+) for 30%±50%, and (3+) for 50%±100% stained, lesional immature epidermal cells
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genotypes associated with skin warts and EV (Orth, 1987; Obalek et al,
1992). Patient A was found to be infected with 11 HPV genotypes
(HPV types 3, 5, 8, 9, 14, 17, 19, 20, 22, 24, 36), and patient B with
®ve HPV genotypes (HPV types 3, 5, 22, 36, 49). The detection of
HPV5 DNA in an SCC specimen of patient B was the ®rst
demonstration of the association of HPV5 with EV cancers (Orth et al,
1980). Molecular cloning and characterization of the genomes of the
HPV5 isolate of patient B and the HPV9 isolate of patient A, and the
identi®cation of HPV5 variants 5aE3 in patient A and 5aE1 in patient B,
have been reported previously (Kremsdorf et al, 1982; Kawase et al,
1996).
Polymerase chain reaction (PCR) ampli®cation and single-strand
conformation polymorphism (SSCP) analysis Thirty-two archival
total DNA preparations obtained from biopsy specimens of lesions at
different stages of tumor progression (Table I), and stored at ±20°C,
were selected because of the availability of paraf®n-embedded samples for
histologic, in situ hybridization, and immunohistochemical studies. PCR
ampli®cation of exons 5 through 8 of the p53 gene was performed using
primers described previously (Ahomadegbe et al, 1995). PCR was carried
out with 100 ng of genomic DNA, 0.3 pmol of each primer, 5 mM of
each deoxynucleotide triphosphate, 2 mCi of a[33P]-dCTP (Amersham;
3000 Ci per mmol), 1 unit of Taq polymerase (Perkin Elmer/Cetus),
2 ml 10 3 PCR buffer (Perkin Elmer/Cetus), and 1.5 mM MgCl2, in a
®nal volume of 20 ml. The reaction mixture was heated to 94°C for
5 min and ampli®cation was performed with 30 cycles of 94°C for 30 s,
58°C for 60 s, 72°C for 60 s, followed by a ®nal extension at 72°C for
5 min, using an automated thermocycler (Perkin Elmer/Cetus). SSCP
analysis was performed using the technique originally described by Orita
et al (1989). Ampli®cation products (2 ml) were diluted 10-fold in 0.1%
sodium dodecyl sulfate with 10 mM ethylenediamine tetraacetic acid
(EDTA), rediluted 1:2 in gel loading solution (95% formamide, 20 mM
EDTA, 0.05% bromophenol blue, 0.5% xylene cyanol), heat-denatured
in boiling water for 2.5 min, chilled on ice, and loaded on a
nondenaturing polyacrylamide gel (0.5 3 Hydrolink MDE gel, Bioprobe
System, in 0.5 3 TBE with 10% glycerol). Electrophoresis was
performed at 50 W for 3 h or at 10 W for 13±15 h at room
temperature. Dried gels were exposed to Hyper®lm b max (Amersham)
at ±70°C. DNAs from human cancer cell lines known to contain
mutations at positions corresponding to amino acids 156, 194, 245, and
273 of the p53 protein were used as positive controls of band shifts. For
each sample, at least two independent PCR-SSCP analyses were carried
out. For 10 of the 32 specimens, PCR ampli®cation was also performed
in the absence of a[33P]-dCTP using a 4-fold higher concentration of
primers. Heat-denatured ampli®cation products were electophoresed
through 12.5% polyacrylamide Genegel Excel gels using a Genephor
apparatus (Pharmacia, Biotech). Running conditions were 600 V, 25
mA, 6 W, for 2 h at 18°C. The bands were visualized using the
PlusOne DNA silver staining kit (Pharmacia, Biotech).
PCR ampli®cation from microdissected tumor sections Sections
5 mm thick were prepared from six paraf®n-embedded specimens (A, f;
B, a; B, e; B, f; B, g; B, i), changing the knife for each specimen. Ten
sections were mounted on slides, deparaf®nized, and lightly stained with
hematoxylin, and tumor tissue was dissected with a small scalpel under a
Zeiss stereomicroscope. Samples were digested in 150 ml of 50 mM Tris-
HCl (pH 8.5), 1 mM EDTA, 0.5% Tween-20, in the presence of 50 mg
of proteinase K (Eurobio, Paris, France), for 24 h at 37°C, and heated at
95°C for 10 min. Aliquots of 10 ml were used for each PCR. Exons 5±8
of the p53 gene were ampli®ed by a seminested PCR. The primers used
in the ®rst step PCR were as above, except for the exon 5 antisense
primer (5¢-CAACCAGCCCTGTCGTCTCTC-3¢). Internal primers
used in the second step PCR were: 5¢-ATCTGTTCACTTGTGCC-
CTG-3¢ (exon 5, sense), 5¢-GGGTCCCCAGGCCTCTGATT-3¢ (exon
6, sense), 5¢-CACAGCAGGCCAGTGTGCAG-3¢ (exon 7, antisense),
and 5¢-GCATAACTGCACCCTTGGTC-3¢ (exon 8, antisense).
The reaction mixtures in AmpliTaq Gold buffer (Perkin Elmer-
Roche) contained 2.5 mM MgCl2, 200 mM dNTPs, 15 mM or 50 mM
of each primer, and 1 U or 2.5 U of AmpliTaq Gold DNA polymerase
(Perkin Elmer-Roche) for the ®rst or second step PCR, respectively. For
the ®rst PCR, DNA was ampli®ed for 45 cycles (1 min at 95°C, 1 min
at 55°C, 2 min at 72°C) with a ®nal extension of 5 min at 72°C. For
the second PCR, 6 ml of the ®rst step PCR products were used as
template and ampli®ed for 35 cycles (30 s at 95°C, 30 s at 55°C, 1 min
at 72°C). Seminested PCR products were separated by electrophoresis in
a 3% NuSieve GTG (BMA, Rockland, ME) agarose gel and puri®ed
using the NucleoSpin Extract 2 in 1 kit (Macherey-Nagel, DuÈren,
Germany).
DNA sequencing The shifted bands were cut out from SSCP gels
and eluted in distilled water (100 ml) at 4°C overnight and 65°C for 2 h.
For two SSCP-positive DNA preparations (specimens A, a, and A, m),
the ampli®cation products were cloned into p-Bluescript II phagemid
(Stratagene) before sequencing. Eluted and cloned DNAs were ampli®ed
with the Expand High Fidelity PCR System (Boehringer, Mannheim)
using the primers described for PCR-SSCP (Ahomadegbe et al, 1995)
and containing universal forward or reverse M13 sequences added to
their 5¢ ends to allow direct sequencing. Ampli®cation products were
sequenced on both strands by the dideoxynucleotide termination
method, using ¯uorescent forward and reverse M13 primers and the ABI
Prism Dye-Primer Cycle Sequencing Kit (PE Applied Biosystems) under
the conditions described by the manufacturer. Puri®ed seminested PCR
products were sequenced using the ABI Prism Big Dye Terminator
Cycle Sequencing Ready Reaction Kit (Applied Biosystems). Sequence
products were analyzed with an ABI Prism 377 DNA sequencer (Perkin
Elmer).
Immunohistochemistry A part of each biopsy specimen was ®xed
in 10% neutral formaldehyde and/or in Carnoy's ¯uid (chloroform 30%,
acetic acid 10%, absolute ethanol 60%), and then embedded in paraf®n.
Five micron sections mounted on poly-L-lysine slides were submitted to
a microwave treatment three times for 5 min in 10 mM citrate buffer,
pH 6, at 750 W. Endogenous peroxidase activity was quenched by an 8
min incubation in 3% hydrogen peroxide. After a 20 min preincubation
in 5% normal horse serum, two mouse monoclonal antibodies were
applied as primary antibodies: anti-p53 DO7 (Dako, Glostrup,
Denmark), 1:50 dilution, 60 min at 37°C, or anti-Bcl-2 clone 124
(Dako), 1:60 dilution, overnight at 4°C. Sections were then incubated
for 30 min with a biotinylated rabbit antimouse antibody (Dako) at a
1:300 dilution, and processed with a streptavidin-biotin-peroxidase
detection system (Dako) as recommended by the manufacturer, using
diaminobenzidine as the chromogen. Counterstaining was performed
with hematoxylin. Sections from a breast, an ovary, and a nasopharyngeal
carcinoma known to express aberrant p53 protein and from a breast and
a tonsil carcinoma known to express high levels of Bcl-2 protein were
used as positive controls. Negative controls were by omission of the
primary antibody.
In situ detection of HPV DNA In situ hybridization was done on
biopsy specimens found to contain a mutated p53 gene. Tritiated DNA
probes (speci®c activity 3±8 3 106 cpm per mg) were prepared by nick-
translation of puri®ed, excised HPV type 5, 8, 9, or 36 DNAs, and were
used at a concentration of 0.2 mg per ml after denaturation at 95°C for
3 min. Processing of formalin-®xed and Carnoy's ¯uid-®xed tissues,
hybridization, washings, and autoradiographic hybrid detection were
performed as described previously (Bergeron et al, 1992). Sections were
counterstained with hematoxylin.
RESULTS
P53 mutations are detected at different stages of tumor
progression in EV PCR-SSCP analysis of exons 5 through 8
of p53 was performed on archival DNA preparations obtained from
32 biopsy specimens. These were taken from two EV patients over
an 8 y period, 39±47 y (patient A) or 44±52 y (patient B) after the
onset of the disease (Table I). Most biopsies contained more than
one (up to three) histopathologic entities. The majority (77.3%) of
the specimens from patient A had previously been found to contain
more than one EV HPV genotype by Southern blot hybridization,
with HPV5 being detected in 11 of 13 (84.6%) in situ and invasive
carcinomas. HPV5 had been found in all specimens of patient B
(Table I). Conclusive results, i.e., band patterns with suf®cient
labeling intensity to allow interpretation, were obtained for 87.5%
(exon 7), 71.9% (exon 6), and 68.7% (exons 5 and 8) of the 32
specimens (Table I). Bands showing a mobility shift compared
with wild-type p53 were observed for eight of the 22 samples that
showed conclusive PCR-SSCP results for at least three exons
(Fig 1). There was no evidence for a loss of the normal allele as
wild-type and mutant bands were codetected, with the shifted
bands showing a weaker labeling intensity in most instances
(Fig 1).
Of the 10 specimens with conclusive PCR-SSCP results for less
than three exons, four could be further analyzed by direct
sequencing of PCR products of DNA extracted from micro-
dissected sections of paraf®n-embedded tissues. Mutations were
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identi®ed in three of them (Table I). Two specimens found to
harbor a mutation (A, f) or to be normal (B, i) by PCR-SSCP
analysis were taken as controls in this experiment (Table I).
On the whole, mutation rates were 15.4% for exon 5, 4% for
exon 6, 16.1% for exon 7, and 3.8% for exon 8. Mutations were
detected in seven (38.9%) of 18 conclusive specimens from patient
A and four (50%) of eight specimens from patient B. Taking into
account the most severe histopathologic change, mutations were
detected in one (33%) specimen with features of benign lesion, two
(40%) AK, three (33.3%) Bowen's CIS, and ®ve (62.5%) SCC.
Evidence for vegetative HPV5 DNA replication was obtained for
seven of the nine specimens of premalignant or invasive lesions
showing a mutation, as tested by in situ hybridization (Fig 2).
HPV8 replication was detected in a benign lesion adjacent to an
HPV5-positive AK. Replication of HPV9 or HPV36 was observed
in the two lesions found within the mutation-positive specimen
with benign features (Table II). Ten of the specimens yielding a
mutation were taken from sun-exposed or occasionally sun-
exposed skin (Table I).
P53 mutations in EV are mutational hotspots in human
cancers Nine mutations were identi®ed by sequencing PCR
products obtained from microdissected tissue sections (three
specimens) or from shifted bands eluted from the polyacrylamide
gels of SSCP analysis (six specimens) (Table II). The nine
mutations were single-nucleotide missense substitutions, and all
mutations affected GC base pairs (Table II). The same mutations
were detected after direct sequencing of two PCR ampli®cation
products or after sequencing several recombinant plasmids. Six of
the nine mutated cytosine residues were located on the transcribed
strand. Seven mutations were observed at sites of adjacent cytosines.
Five of them corresponded to a C®T transition, ®tting with the
UVB ®ngerprint p53 mutations found in the majority of NMSC in
the general population (Dumaz et al, 1994; Nataraj et al, 1995;
Brash, 1997). The two others involved C®G and C®A
transversions. Two mutations did not involve a dipyrimidine site
or CpG sequences and were G:C®A:T transitions (Table II).
Most mutated amino acid residues (codons 130, 135, 173, 248, 249,
258) were located in the conserved regions II±V of the DNA-
binding core domain of the p53 protein. All affected codons were
located at mutational hotspots found in human cancers (Walker et
al, 1999). Only two (codon 248 found mutated twice and codon
258) corresponded to mutation hotspots reported previously for
NMSC (Ziegler et al, 1993).
The p53 protein is aberrantly expressed in EV
lesions Immunoreactive p53 protein was detected in 83.3% of
the biopsy specimens, using a monoclonal antibody (DO7)
recognizing both wild-type and mutated p53 proteins (Table I).
Nuclear staining involving 30%±50% (2+) or 50%±100% (3+) of the
immature lesional keratinocytes was observed in 72.7% of the
specimens diagnosed as microinvasive or invasive carcinoma, 55.6%
of the CIS, 37.5% of the AK, and one of three benign lesions
(Table III, Fig 3). Overall, this corresponds to 45.5% and 87.5% of
the specimens collected from patients A and B, respectively.
Terminally differentiating keratinocytes were variably stained. No
staining or only few scattered positive nuclei were observed in the
normal epidermis, except for two specimens (B, d, and B, e) that
showed a compact staining pattern, either restricted to the basal layer
or extending throughout the apparently normal epidermis adjacent
to an immunoreactive SCC (data not shown). A marked (2+ or 3+)
p53 staining of the immature keratinocytes was observed in nine
(81.8%) of the 11 specimens with a p53 mutation (Fig 3A, C, D),
but also in seven (50%) of 14 specimens for which no mutation could
be detected (Fig 3B, F) and one (20%) of ®ve specimens for which
the PCR-SSCP analysis was not conclusive (Fig 3E). When a
biopsy contained more than one lesion, the same level of
immunostaining was often observed for adjacent lesions, which
most probably represent different stages of the tumor progression
(AK and CIS or CIS and microinvasive SCC) (Table II).
Figure 1. SSCP analysis of ampli®ed p53 exons from EV biopsy
specimens. Exons 5 through 8 were PCR ampli®ed in the presence of
[a33P]-dCTP. PCR products were heat-denatured and single-stranded
DNA molecules were fractionated on nondenaturing polyacrylamide gels
and detected by autoradiography as described in Materials and Methods.
Capital and lower case letters given on the top of the lanes correspond
to the patients and specimens described in Table I. Aberrant p53 DNA
migration patterns (+) show a band or bands with altered migration
compared with the wild-type p53 DNA migration patterns (±).
Figure 2. In situ detection of HPV5 DNA in lesions with a
mutated p53 gene. Sections of an AK (A; specimen A, a) and a CIS
(B; specimen A, f) were hybridized with a tritiated HPV5 DNA probe.
Hybrids are detected in the nuclei of upper differentiating cells, where
vegetative viral DNA replication occurs (Orth et al, 1980), and in
differentiated cells. Scale bar: 100 mm.
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The Bcl-2 protein is not expressed in EV SCC and their
precursor lesions As half of EV lesions for which there was no
evidence for p53 mutations showed high p53 protein
immunoreactivity, we analyzed all specimens showing features of
AK, CIS, or NMSC for antiapoptotic Bcl-2 protein expression,
which is able to block p53-dependent apoptosis (White, 1996;
Amundson et al, 1998). High levels of cytoplasmic Bcl-2 protein
were detected in the only specimen of basal cell carcinoma (BCC),
and immunostaining of consecutive sections showed that Bcl-2 and
p53 proteins were congruently expressed (Fig 3F, G). No p53
mutation was detected in this tumor (Table I). In contrast, no
immunohistochemical evidence for the expression of Bcl-2 was
obtained for the other EV preinvasive or invasive lesions tested.
DISCUSSION
Inactivation of the p53 gene resulting from UVB-induced muta-
tions is a major event in skin carcinogenesis in the general
population (Brash, 1997). In contrast, p53 mutations are seldom
found in genital cancers (Park et al, 1994). Abrogation of the
function of p53 protein through its interaction with the viral E6
oncoprotein, however, plays a major part in the carcinogenesis
associated with genital HPV genotypes (Howley, 1996). Patients
suffering from EV are at high risk of NMSC due to their genetically
determined predisposition to infection with the oncogenic HPV5.
Analyses of the p53 status in EV carcinogenesis have been
hampered by the rarity of the disease. To address the question,
we took advantage of the availability of a collection of total DNA
and paraf®n-embedded tissues prepared from lesion specimens from
two HPV5-infected EV patients taken over an 8 y period. The data
presented here support the hypothesis of a dysfunction of the p53
gene in EV tumors, and provide clues concerning the mechanisms
that could contribute to the development of NMSC in EV patients.
Mutations in the p53 gene were detected at different stages of
tumor progression, i.e., in one (33.3%) of three benign lesions, two
(40%) of ®ve AK, three (33.3%) of nine Bowen's CIS, and ®ve
(62.5%) of nine SCC. HPV5 replication, as detected by in situ
hybridization, was observed in most preinvasive and invasive
lesions harboring a mutation in the p53 gene. Mutation rates were
within the range reported for premalignant lesions of the skin and
NMSC in the general population (Brash et al, 1991; MoleÁs et al,
1993; Ziegler et al, 1993; 1994; Nataraj et al, 1995) and in
immunosuppressed patients (McGregor et al, 1997). It is likely that
mutation rates were underestimated because our study involved
only exons 5±8, which encode the DNA-binding core domain of
the p53 protein. Moreover, the occurrence of several types of
lesions within most specimens along with the presence of normal
tissue must have decreased the sensitivity of detection of mutated
alleles and precluded the disclosure of loss of the normal allele in
SSCP patterns with band shifts. The nine mutations identi®ed by
sequencing are all missense, affect highly conserved amino acid
residues essential for p53 structure and function, and correspond to
mutational hotspots found in human cancers (Walker et al, 1999).
For example, arginine 248, which was changed to glutamine or
tryptophan in two AK, plays a crucial role in sequence-speci®c
DNA binding of the p53 protein (Cho et al, 1994). Thus, p53
mutations are likely to play a role in EV carcinogenesis, by
counteracting the tumor-suppressive apoptotic and growth-arrest-
ing responses to various p53-activating stresses encountered during
tumor progression (Evan and Vousden, 2001).
Further support for a role of a dysfunction of the p53 tumor
suppressor gene in EV carcinogenesis is provided by the marked
p53 immunoreactivity observed in 82% of the lesions with a
mutation and in 50% of the specimens with no detected mutation.
A p53 immunostaining had previously been reported for EV warts
showing variable degrees of atypia in the absence of detected p53
mutation (Pizarro et al, 1995). This contrasts with the lack of p53
staining in warts of non-EV patients (McGregor et al, 1994; Pizarro
Table II. p53 mutations in EV lesions
Patient,
specimena
p53
exon Codon Sequencec
Base
change
Amino acid
change
In situ detection
p53 proteind HPV DNAe
B, e 5 130 cCtc C:G®T:A Leu®Phe cis: 3+ SCC: 3+ 5
B, b 135 tGc G:C®A:T Cys®Tyr mscc, cis: 3+ ak: 2+ ±
A, c 173 tGtg G:C®A:T Val®Met cis: 3+ 5
A, i ndb nd nd nd bl: 2+; bl-; ns: ± 36, 9
A, g 6 nd nd nd nd cis: ±; ak: +; ns: ± 5
B, f 7 232 cCac C:G®T:A His®Tyr SCC, 3+ nd
A, a 248 cCgg C:G®T:A Arg®Trp ak: 2+; bl: + 5, 8
B, a 248 cGg G:C®A:T Arg®Gln ak: 3+ ±
A, m 249 aGg G:C®C:G Arg®Thr mscc, cis: 3+; ak, ns:± 5
A, f 258 gGaa G:C®A:T Glu®Lys cis, ak: + 5
A, k 8 266 gGa G:C®T:A Gly®Val mscc: 2+ 5
aDescribed in Table I.
bnd, not determined; sequencing not done after PCR-SSPC positive results.
cThe sequence is written 5¢®3¢ for the coding strand. The capital letter indicates the mutated base.
dak, AK; bl, benign lesion; cis, CIS; mscc, microinvasive SCC; ns, normal skin. p53 immunoreactivity was scored as indicated in legend to Table I.
eViral DNA replication as detected by in situ hybridization. The HPV36-associated benign lesion was p53-positive. The negative specimens had been found to be HPV5-
positive by Southern blot hybridization (Table I).
Table III. Immunoreactivity of p53 protein in EV tumor
specimens
Histologya
No. of
specimens
p53 stainingb
± + 2+ 3+
Basal cell carcinoma 1 0 0 1 0
Squamous cell carcinoma 10 1 2 2 5
Carcinoma in situ 9 1 3 1 4
Actinic keratosis 8 2 3 1 2
Benign lesion 3 2 0 1 0
aMost severe histologic change.
bTwo specimens (one benign lesion, one microinvasive carcinoma) were non-
conclusive. One specimen contained two benign lesions. ± corresponds to less than
1%, and +, 2+, and 3+ to 1%±30%, 30%±50%, and 50%±100% stained immature
lesional epidermal cells, respectively.
VOL. 117, NO. 4 OCTOBER 2001 p53 MUTATIONS IN EV CARCINOGENESIS 939
et al, 1995). It has been reported that the p53 immunoreactivity
frequently observed in skin neoplasias in the general population
does not always correlate with the detection of a mutation
(Campbell et al, 1993; Ziegler et al, 1993; Ren et al, 1996). This
may correspond to missed mutations or to a stabilization of the
wild-type p53 protein. Inhibition of MDM2-mediated ubiquitin-
dependent degradation of p53 protein may occur in response to
endogenous stresses, such as an inappropriate growth-promoting
signal resulting from the expression of viral oncoproteins (Lohrum
and Vousden, 1999; Vogelstein et al, 2000). A stabilization of the
p53 protein is induced in human keratinocytes immortalized by the
HPV16 E7 gene (Demers et al, 1994). HPV5 E7 protein binds Rb
protein, and this is likely to generate a proliferative signal
(Yamashita et al, 1993; Hiraiwa et al, 1996). The E2F-1 transcrip-
tion factor released from its inactive Rb-bound form may activate
the expression of the p14 ARF protein, which binds to the MDM2
protein and inhibits its activity (Vogelstein et al, 2000). Although
the E6 proteins of oncogenic EV HPV genotypes do not promote
p53 degradation (Steger and P®ster, 1992; Elbel et al, 1997), HPV5
E6 protein has been shown to interfere with p53-induced G1 arrest
and apoptosis in UV-irradiated cell lines (Jackson and Storey,
2000). The antiapoptotic Bcl-2 protein is expressed in BCC but
rarely in SCC in the general population (Wikonkal et al, 1997).
This protein was not detected in EV lesions, with the exception of
the only BCC studied, suggesting that it is not involved in EV
carcinogenesis. It has recently been proposed that HPV5 E6 protein
could exert an antiapoptotic effect by promoting the proteolytic
degradation of the UV-induced pro-apoptotic Bak protein (Jackson
Figure 3. Positive p53 immunostaining of lesions from two EV patients. Six of the EV specimens described in Table I are illustrated. (A)
Benign EV macular lesion (A, i) with a nuclear staining con®ned to basal cells; (B) CIS adjacent to a positive SCC (A, n) with a labeling sparing the
super®cial differentiating cells; (C) AK (B, a) with a staining of almost all immature keratinocytes and lack of staining of a hair follicle; (D), (E)
microinvasive (A, m) and invasive (B, d) SCC with a strong staining of almost all undifferentiated cells; (F), (G) consecutive sections of a BCC (A, p)
showing a congruent moderate p53 immunoreactivity and strong Bcl-2 immunostaining. Scale bar: 30 mm.
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et al, 2000). Whether the activity of p53 protein is affected in vivo
by HPV5 E6 and E7 oncoproteins expressed from their own
promoters remains to be established.
All nine p53 mutations identi®ed in EV lesions affect GC base
pairs. Five were C®T transitions at dicytidine sites, including three
found at mutation hotspots unique for NMSC (codons 248 and
258) (Ziegler et al, 1993). These can be considered as UV signature
mutations (Dumaz et al, 1994; Brash, 1997). Interestingly, both
patients had been found to have a normal UV-induced DNA repair
in the epidermis (Proniewska and Jablonska, 1980). The four other
base substitutions occurred at mutational hotspots identi®ed in
internal malignant tumors (Walker et al, 1999). Two were C®T
transitions at a nondipyridimine site. The two transversions
occurring at GG:CC sequences are not informative because they
can be generated by many different mutagens (Ziegler et al, 1993).
None was found at a CpG dinucleotide, however, which excludes
the deamination of a methylated cytosine, a frequent endogenous
mechanism of DNA damage (Greenblatt et al, 1994). These four
mutations could correspond to DNA replication errors or could
result from unrepaired DNA lesions caused by exogenous or
endogenous mutagens other than genotoxic UVB radiation
(Hollstein et al, 1998), as has already been suggested for skin
tumors of Japanese patients (Takata et al, 1997). Mutagenic agents
could be reactive oxygen species generated from oxidative
metabolism, or resulting from exposure to the UVA component
of sunlight or to ionizing radiation (Perchellet et al, 1995; Wang et
al, 1998; Pourzand and Tyrrell, 1999). Interestingly, patient B
received X-ray therapy for forehead SCC in 1972 and 1977.
In conclusion, a dysfunction of the p53 gene is likely to play a
part in EV carcinogenesis, either due to UVB-induced p53
mutations, as in NMSC in the general population, or involving
other mutagens or mechanisms. Whether the genetic defects
speci®c to EV (Ramoz et al, 2000), and the resulting high level of
expression of the E6 and E7 proteins of HPV5 and related
genotypes in EV keratinocytes, lead to increased mutation rates or
to a dysfunction of the wild-type p53 protein remains to be
established.
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